Shayna Sarosiek, MD

Assistant Professor, Medicine

Shayna Sarosiek
820 Harrison Ave

Biography

Dr. Shayna Sarosiek, MD, MS is an Assistant Professor of Medicine in Hematology and Medical Oncology for the Boston University School of Medicine. Dr. Sarosiek completed her fellowship in Hematology & Oncology and Amyloidosis at Boston Medical Center, in which she was Chief Fellow in Hematology & Oncology. Dr. Sarosiek, also completed her residency and internship at Boston Medical Center. She received her MD from the University of Miami School of Medicine, her MS in Biomedicine from Barry University and her BA from Wake Forest University.

Other Positions

  • Member, Amyloidosis Center, Boston University

Education

  • University of Miami School of Medicine, MD

Classes Taught

  • GMS MM 707
  • MED MS 220

Publications

  • Published on 9/1/2020

    Sarosiek S, Zheng L, Sloan JM, Quillen K, Brauneis D, Sanchorawala V. Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis. Blood Cancer J. 2020 Sep 01; 10(8):88. PMID: 32873776.

    Read at: PubMed
  • Published on 7/31/2020

    Szalat R, Sarosiek S, Havasi A, Brauneis D, Sloan JM, Sanchorawala V. Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis. Leukemia. 2020 Jul 31. PMID: 32737434.

    Read at: PubMed
  • Published on 7/18/2020

    Prilutskiy A, Kritselis M, Shevtsov A, Yambayev I, Vadlamudi C, Zhao Q, Kataria Y, Sarosiek SR, Lerner A, Sloan JM, Quillen K, Burks EJ. SARS-CoV-2 Infection-Associated Hemophagocytic Lymphohistiocytosis. Am J Clin Pathol. 2020 Jul 18. PMID: 32681166.

    Read at: PubMed
  • Published on 6/19/2020

    Dumas B, Yameen H, Sarosiek S, Sloan JM, Sanchorawala V. Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen. Amyloid. 2020 Jun 19; 1-6. PMID: 32551974.

    Read at: PubMed
  • Published on 5/27/2020

    Dennis M, Maoz A, Cirstea D, Patel A, Lerner A, Sarosiek S. Treatment disparities in minority groups with multiple myeloma at a safety-net hospital. Leuk Lymphoma. 2020 May 27; 1-4. PMID: 32460648.

    Read at: PubMed
  • Published on 4/30/2020

    Sanchorawala V, Sarosiek S, Schulman A, Mistark M, Migre ME, Cruz R, Sloan JM, Brauneis D, Shelton AC. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study. Blood. 2020 Apr 30; 135(18):1541-1547. PMID: 31978210.

    Read at: PubMed
  • Published on 4/1/2020

    White PS, Dennis M, Jones EA, Weinberg JM, Sarosiek S. Risk Factors for Development of Hypocalcemia in Patients With Cancer Treated With Bone-Modifying Agents. J Natl Compr Canc Netw. 2020 04; 18(4):420-427. PMID: 32259788.

    Read at: PubMed
  • Published on 3/10/2020

    Staron A, Burks EJ, Lee JC, Sarosiek S, Sloan JM, Sanchorawala V. Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis. Blood Adv. 2020 Mar 10; 4(5):880-884. PMID: 32130406.

    Read at: PubMed
  • Published on 3/9/2020

    Angel-Korman A, Stern L, Angel Y, Sarosiek S, Menn-Josephy H, Francis J, Ghai S, Sloan JM, Sanchorawala V, Havasi A. The Role of Kidney Transplantation in Monoclonal Ig Deposition Disease. Kidney Int Rep. 2020 Apr; 5(4):485-493. PMID: 32274452.

    Read at: PubMed
  • Published on 10/23/2019

    Sarosiek S, Sanchorawala V. Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives. J Blood Med. 2019; 10:373-380. PMID: 31695543.

    Read at: PubMed

View 27 more publications: View full profile at BUMC

View all profiles